A database of protein Phosphorylation and Drug Information of Hepatocellular Carcinoma Biomarkers

• Main Authors: Ching-Hsuan Chien, 簡靖軒
• Other Authors: 陳玉婷
• Format: Others
• Language: en_US
• Published: 2018
• Online Access: http://ndltd.ncl.edu.tw/handle/9wn2d6

碩士 === 國立中興大學 === 基因體暨生物資訊學研究所 === 106 === Hepatocellular carcinoma (HCC) is the second leading cause of cancer death globally. The symptoms of liver cancer in the early stages are not obvious, thus it is not easy to diagnose.As patients were diagnosed, it usually reaches the late stage, and the tumor may have also spread to lymph nodes but not to other parts of the body. Therefore, patients with hepatocellular carcinoma usually have a poor prognosis. Genome-wide molecular biology studies may help investigate benefit the biology insight of HCC development. According to the importance of phosphorylation on signal transduction, several protein kinase inhibitors have been developed for HCC treatment to improve survival of HCC patients. Our group had built DPPHCC database to provide a comprehensive HCC phosphorylated biomarker database and prediction platform. DPPHCC incorporated HCC related genes and their related pathway, phosphorylation related motif and its corresponding protein kinase, and protein expression profiles. DPPHCC obtained HCC-611, MKA and GOCU databases, and the evaluation systems for HCC marker and phosphorylation prediction. While we found some bugs in DPPHCC, thus we try to update the databases, debug the system, and incorporate the Drug information. dBMHCC contains 611 HCC significant genes, 234 HCC related pathways, 17 phosphorylation related motifs and their 255 corresponding protein kinases, 5955 HCC biomarkers, 1077 predicted HCC phosphorylated biomarkers (HCCPMs). Among the top 10 HCCPMs predicted by dBMHCC, the methionine adenosyltransferase 2B (MAT2B) and acireductone dioxygenase 1 (ADI1) were involved HCC development and hepatitis C virus infection, respectively. Platelet-derived growth factor receptor alpha (PDGFRA), which has the highest evaluation scores, was identified as the target of 1 HCC drug (Regorafenib), 5 cancer drugs, and 4 non-cancer drugs. The cancer drugs may be investigated the feasibility in HCC treatment. dBMHCC is an open resource for HCC phosphorylated biomarkers, which provides expression profiles, evidence type and drug information to support researchers investigating the HCC development and designing the novel diagnosis and drug.